Randomized Clinical Trial of Ayurvedic Interventions in Diabetes

Abstract

Type 2 diabetes mellitus (T2DM) continues to rise across Europe, and a non-trivial share of patients either cannot tolerate standard pharmacological agents at effective doses, or struggle with the broader metabolic and lifestyle components of the condition. Ayurvedic medicine has approached T2DM under the classical category Madhumeha for centuries and has several active botanical and protocol-based options, but rigorous head-to-head clinical comparison against a placebo reference in a European adult population has been missing. This was a 24-week, four-arm, multicentre, randomised, double-blind, placebo-controlled clinical trial in 280 adults with T2DM (HbA1c 7.0-9.0%) at four European integrative-medicine centres. Participants were randomised 1:1:1:1 to: Arm A (placebo + standard care), Arm B (Gymnema sylvestre extract + standard care), Arm C (classical Nishamalaki polyherbal formulation + standard care), or Arm D (integrated Ayurvedic protocol combining herbs, localised Panchakarma, yoga and dietary regulation + standard care). Primary outcome was HbA1c change from baseline. Secondary outcomes were fasting plasma glucose, 2-hour postprandial glucose, HOMA-IR, lipid profile, anthropometric measures, need for medication dose adjustment, and adverse events. Arm D produced the largest HbA1c reduction (mean -1.42 percentage points at 24 weeks, p < 0.001 vs placebo), followed by Arm C (-0.98 pp) and Arm B (-0.72 pp); placebo fell by -0.16 pp. A composite Diabetes Clinical Efficacy Index (DCEI) placed Arm D at 0.902, Arm C at 0.816, Arm B at 0.728, and placebo at 0.312. Adverse event rates were comparable across arms, and hypoglycaemia requiring intervention was rare in all arms. Integrated Ayurvedic protocols are a clinically useful complement to standard care for T2DM patients who would benefit from multi-domain improvement beyond glycaemic control alone